Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.

MLA

Bischof, Matthias, et al. “Matching-Adjusted Indirect Treatment Comparison of Onasemnogene Abeparvovec and Nusinersen for the Treatment of Symptomatic Patients with Spinal Muscular Atrophy Type 1.” Current Medical Research and Opinion, vol. 37, no. 10, Oct. 2021, pp. 1719–30. EBSCOhost, https://doi.org/10.1080/03007995.2021.1947216.

APA

Bischof, M., Lorenzi, M., Lee, J., Druyts, E., Balijepalli, C., & Dabbous, O. (2021). Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Current Medical Research and Opinion, 37(10), 1719–1730. https://doi.org/10.1080/03007995.2021.1947216

Chicago

Bischof, Matthias, Maria Lorenzi, Jennifer Lee, Eric Druyts, Chakrapani Balijepalli, and Omar Dabbous. 2021. “Matching-Adjusted Indirect Treatment Comparison of Onasemnogene Abeparvovec and Nusinersen for the Treatment of Symptomatic Patients with Spinal Muscular Atrophy Type 1.” Current Medical Research and Opinion 37 (10): 1719–30. doi:10.1080/03007995.2021.1947216.